-
1
-
-
0027239723
-
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment
-
1. Brodeur GM, Prichard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-77
-
(1993)
J Clin Oncol
, vol.11
, pp. 1466-1477
-
-
Brodeur, G.M.1
Prichard, J.2
Berthold, F.3
-
2
-
-
0029977194
-
Role of ploidy, chromosome 1p, and schwann cells in the maturation of neuroblastoma
-
2. Ambros IM, Zellner A, Roald B, et al. Role of ploidy, chromosome 1p, and schwann cells in the maturation of neuroblastoma. N Engl J Med 1996; 334: 1505-11
-
(1996)
N Engl J Med
, vol.334
, pp. 1505-1511
-
-
Ambros, I.M.1
Zellner, A.2
Roald, B.3
-
3
-
-
0003457007
-
-
Mainz: German Childhood Cancer Registry
-
3. Kaatsch P, Kaletsch U, Spix C, et al. Annual report 1998, German Childhood Cancer Registry. Mainz: German Childhood Cancer Registry, 1999: 72, 88
-
(1999)
Annual Report 1998, German Childhood Cancer Registry
, pp. 72
-
-
Kaatsch, P.1
Kaletsch, U.2
Spix, C.3
-
4
-
-
0345294452
-
Neuroblastoma in Europe: Differences in the pattern of disease in the UK
-
4. Powell JE, Estève J, Mann JR, et al. Neuroblastoma in Europe: differences in the pattern of disease in the UK. Lancet 1998; 352: 682-7
-
(1998)
Lancet
, vol.352
, pp. 682-687
-
-
Powell, J.E.1
Estève, J.2
Mann, J.R.3
-
5
-
-
0031417490
-
The current contribution of molecular factors in risk estimation in neuroblastoma patients
-
5. Berthold F, Sahin K, Christiansen H, et al. The current contribution of molecular factors in risk estimation in neuroblastoma patients. Eur J Cancer 1997; 33: 2092-7
-
(1997)
Eur J Cancer
, vol.33
, pp. 2092-2097
-
-
Berthold, F.1
Sahin, K.2
Christiansen, H.3
-
6
-
-
0028181863
-
Multivariate evaluation of prognostic factors in localized neuroblastoma
-
6. Berthold F, Kassenböhmer R, Zischang J. Multivariate evaluation of prognostic factors in localized neuroblastoma. Am J Pediatr Hematol Oncol 1994; 16: 107-15
-
(1994)
Am J Pediatr Hematol Oncol
, vol.16
, pp. 107-115
-
-
Berthold, F.1
Kassenböhmer, R.2
Zischang, J.3
-
7
-
-
0013656729
-
Evaluation of catecholamine metabolites, mIBG scan and bone marrow cytology as response markers in stage 4 neuroblastoma
-
In press
-
7. Hero B, Hunneman DH, Gahr M, et al. Evaluation of catecholamine metabolites, mIBG scan and bone marrow cytology as response markers in stage 4 neuroblastoma. Med Pediatr Oncol. In press
-
Med Pediatr Oncol
-
-
Hero, B.1
Hunneman, D.H.2
Gahr, M.3
-
8
-
-
0022388606
-
Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas
-
8. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111-6
-
(1985)
N Engl J Med
, vol.313
, pp. 1111-1116
-
-
Seeger, R.C.1
Brodeur, G.M.2
Sather, H.3
-
9
-
-
0031727309
-
Prognostic significance of MYCN oncogene expression in childhood Neuroblastoma
-
9. Bordow SB, Norris MD, Haber PS, et al. Prognostic significance of MYCN oncogene expression in childhood Neuroblastoma. J Clin Oncol 1998; 16: 3286-94
-
(1998)
J Clin Oncol
, vol.16
, pp. 3286-3294
-
-
Bordow, S.B.1
Norris, M.D.2
Haber, P.S.3
-
10
-
-
0026538759
-
Prognostic importance of DNA flow cytometrical, histopathological and immunohistochemical parameters in neuroblastomas
-
10. Carlsen N, Ørnvold K, Christensen IJ, et al. Prognostic importance of DNA flow cytometrical, histopathological and immunohistochemical parameters in neuroblastomas. Virchows Arch A Pathol Anat Histopathol 1992; 420: 411-8
-
(1992)
Virchows Arch A Pathol Anat Histopathol
, vol.420
, pp. 411-418
-
-
Carlsen, N.1
ØRnvold, K.2
Christensen, I.J.3
-
11
-
-
0025979843
-
Clinical relevance of tumor cell ploidy and N.myc gene amplification in childhood neuroblastoma: A pediatric oncology group study
-
11. Look AT, Hayes A, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N.myc gene amplification in childhood neuroblastoma: a pediatric oncology group study. J Clin Oncol 1991; 9: 581-91
-
(1991)
J Clin Oncol
, vol.9
, pp. 581-591
-
-
Look, A.T.1
Hayes, A.2
Shuster, J.J.3
-
12
-
-
0023835841
-
Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma
-
12. Christiansen H, Lampert F. Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma. Br J Cancer 1988; 57: 121-6
-
(1988)
Br J Cancer
, vol.57
, pp. 121-126
-
-
Christiansen, H.1
Lampert, F.2
-
13
-
-
13344275864
-
Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma
-
13. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996; 334: 225-30
-
(1996)
N Engl J Med
, vol.334
, pp. 225-230
-
-
Caron, H.1
Van Sluis, P.2
De Kraker, J.3
-
14
-
-
0028790325
-
The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma
-
14. Gehring M, Berthold F, Edler L, et al. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res 1995; 55: 5366-9
-
(1995)
Cancer Res
, vol.55
, pp. 5366-5369
-
-
Gehring, M.1
Berthold, F.2
Edler, L.3
-
15
-
-
0028023048
-
Translocation involving 1p and 17q is a recurrent genetic alteration of human Neuroblastoma cells
-
15. Savelyeva L, Corvi R, Schwab M. Translocation involving 1p and 17q is a recurrent genetic alteration of human Neuroblastoma cells. Am J Hum Genet 1994; 55: 334-40
-
(1994)
Am J Hum Genet
, vol.55
, pp. 334-340
-
-
Savelyeva, L.1
Corvi, R.2
Schwab, M.3
-
16
-
-
0028944776
-
Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma
-
16. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol 1995; 24: 215-21
-
(1995)
Med Pediatr Oncol
, vol.24
, pp. 215-221
-
-
Caron, H.1
-
17
-
-
0030031845
-
Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma
-
17. Norris MD, Bordow SB, Marshall GM, et al. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996; 334: 231-8
-
(1996)
N Engl J Med
, vol.334
, pp. 231-238
-
-
Norris, M.D.1
Bordow, S.B.2
Marshall, G.M.3
-
18
-
-
84993876589
-
Correlating telomerase activity levels with human neuroblastoma outcomes
-
18. Hiyama E, Hiyama K, Yokoyama T, et al. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995; 1: 249-55
-
(1995)
Nat Med
, vol.1
, pp. 249-255
-
-
Hiyama, E.1
Hiyama, K.2
Yokoyama, T.3
-
19
-
-
0033083005
-
The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors
-
19. Maitra A, Yashima K, Rathi A, et al. The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors. Cancer 1991; 85: 741-9
-
(1991)
Cancer
, vol.85
, pp. 741-749
-
-
Maitra, A.1
Yashima, K.2
Rathi, A.3
-
20
-
-
0027285262
-
Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in Neuroblastoma with favorable prognosis
-
20. Kogner P, Barbany G, Dominici C, et al. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in Neuroblastoma with favorable prognosis. Cancer Res 1993; 53: 2044-50
-
(1993)
Cancer Res
, vol.53
, pp. 2044-2050
-
-
Kogner, P.1
Barbany, G.2
Dominici, C.3
-
21
-
-
0027531016
-
Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma
-
21. Nakagawara A, Arima-Nakagawara M, Scavarda N, et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328: 847-54
-
(1993)
N Engl J Med
, vol.328
, pp. 847-854
-
-
Nakagawara, A.1
Arima-Nakagawara, M.2
Scavarda, N.3
-
22
-
-
0028011502
-
Absence of CD44-standard in human neuroblastoma correlates with histological dedifferentiation, N-myc amplification and reduced survival probability
-
22. Terpe HJ, Christiansen H, Berthold F, et al. Absence of CD44-standard in human neuroblastoma correlates with histological dedifferentiation, N-myc amplification and reduced survival probability. Cell Death Differ 1994; 1: 123-8
-
(1994)
Cell Death Differ
, vol.1
, pp. 123-128
-
-
Terpe, H.J.1
Christiansen, H.2
Berthold, F.3
-
23
-
-
0031427274
-
Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma
-
23. Combaret V, Gross N, Lasset C, et al. Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma. Eur J Cancer 1997; 33: 2101-5
-
(1997)
Eur J Cancer
, vol.33
, pp. 2101-2105
-
-
Combaret, V.1
Gross, N.2
Lasset, C.3
-
24
-
-
0002976297
-
Sind Spontanregressionen beim Neuroblastom verspätete embryofetale Involutionen?
-
Heim ME, Schwarz R, editors. Stuttgart: Schattauer Verlag
-
24. Berthold F, Hero B, Jobke A, et al. Sind Spontanregressionen beim Neuroblastom verspätete embryofetale Involutionen? In: Heim ME, Schwarz R, editors. Spontanremissionen bei krebserkrankungen. Stuttgart: Schattauer Verlag, 1998: 84-94
-
(1998)
Spontanremissionen Bei Krebserkrankungen
, pp. 84-94
-
-
Berthold, F.1
Hero, B.2
Jobke, A.3
-
25
-
-
0030597499
-
A population-based study of the usefulness of screening for neuroblastoma
-
25. Woods WG, Tuchman M, Robison LL, et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet 1996; 348: 1682-7
-
(1996)
Lancet
, vol.348
, pp. 1682-1687
-
-
Woods, W.G.1
Tuchman, M.2
Robison, L.L.3
-
26
-
-
0016687593
-
Differentiation of neuroblastoma cells in culture
-
26. Prasad KN. Differentiation of neuroblastoma cells in culture. Biol Rev Camb Philos Soc 1975; 50: 129-65
-
(1975)
Biol Rev Camb Philos Soc
, vol.50
, pp. 129-165
-
-
Prasad, K.N.1
-
27
-
-
0029004432
-
Antiproliferative potential of cytostatic drugs on neuroblastoma cells in vitro
-
27. Fulda S, Honer M, Menke-Moellers I, et al. Antiproliferative potential of cytostatic drugs on neuroblastoma cells in vitro. Eur J Cancer 1995; 31A: 616-21
-
(1995)
Eur J Cancer
, vol.31 A
, pp. 616-621
-
-
Fulda, S.1
Honer, M.2
Menke-Moellers, I.3
-
28
-
-
0003154954
-
Treatment of advanced neuroblastoma: The european experience
-
Brodeur GM, Sawada T, Tsuchida Y, et al, editors. Amsterdam: Elsevier Press
-
28. Hartmann O, Berthold F. Treatment of advanced neuroblastoma: the european experience, In: Brodeur GM, Sawada T, Tsuchida Y, et al, editors. Neuroblastoma. Amsterdam: Elsevier Press, 2000: 436-52
-
(2000)
Neuroblastoma
, pp. 436-452
-
-
Hartmann, O.1
Berthold, F.2
-
29
-
-
0013675406
-
Treatment of advanced neuroblastoma: The Japanese experience
-
Brodeur GM, Sawada T, Tsuchida Y, et al., editors. Amsterdam: Elsevier Press
-
29. Tsuchida Y, Kaneko M. Treatment of advanced neuroblastoma: the Japanese experience, In: Brodeur GM, Sawada T, Tsuchida Y, et al., editors. Neuroblastoma. Amsterdam: Elsevier Press, 2000: 453-70
-
(2000)
Neuroblastoma
, pp. 453-470
-
-
Tsuchida, Y.1
Kaneko, M.2
-
30
-
-
0003154954
-
Treatment of advanced neuroblastoma: The U.S. experience
-
Brodeur GM, Sawada T, Tsuchida Y, et al., editors. Amsterdam: Elsevier Press
-
30. Matthay KK, Castleberry RP. Treatment of advanced neuroblastoma: the U.S. experience. In: Brodeur GM, Sawada T, Tsuchida Y, et al., editors. Neuroblastoma. Amsterdam: Elsevier Press, 2000: 417-36
-
(2000)
Neuroblastoma
, pp. 417-436
-
-
Matthay, K.K.1
Castleberry, R.P.2
-
31
-
-
0020059019
-
High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma
-
31. Pritchard J, McElwain TJ, Graham-Pole J. High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Br J Cancer 1982; 45: 86-94
-
(1982)
Br J Cancer
, vol.45
, pp. 86-94
-
-
Pritchard, J.1
McElwain, T.J.2
Graham-Pole, J.3
-
32
-
-
0033554684
-
Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retmoic acid
-
32. Matthay K, Villablanca JG, Seeger RC, et al. Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retmoic acid. N Engl J Med 1999; 341: 1165-73
-
(1999)
N Engl J Med
, vol.341
, pp. 1165-1173
-
-
Matthay, K.1
Villablanca, J.G.2
Seeger, R.C.3
-
33
-
-
0031418315
-
Stage IV neuroblastoma in patients over 1 year of age at diagnosis: Consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by in vitro mafosfamide-purged autologous bone marrow transplantation
-
33. Hartmann O, Valteau-Couanet D, Benhamou E, et al. Stage IV neuroblastoma in patients over 1 year of age at diagnosis: consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by in vitro mafosfamide-purged autologous bone marrow transplantation. Eur J Cancer 1997; 33: 2126-9
-
(1997)
Eur J Cancer
, vol.33
, pp. 2126-2129
-
-
Hartmann, O.1
Valteau-Couanet, D.2
Benhamou, E.3
-
34
-
-
0031431549
-
1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of european experience and conclusions
-
34. Philip T, Ladenstein R, Lasset C, et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of european experience and conclusions. Eur J Cancer 1997; 33: 2130-5
-
(1997)
Eur J Cancer
, vol.33
, pp. 2130-2135
-
-
Philip, T.1
Ladenstein, R.2
Lasset, C.3
-
35
-
-
0032401845
-
Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy
-
35. Keshelava N, Seeger RC, Groshen S, et al. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998; 58: 5396-405
-
(1998)
Cancer Res
, vol.58
, pp. 5396-5405
-
-
Keshelava, N.1
Seeger, R.C.2
Groshen, S.3
-
36
-
-
0025826599
-
Expression of mdr-1/P-glycoprotein in human neuroblastoma
-
36. Bates ES, Shieh CY, Tsokos M. Expression of mdr-1/P-glycoprotein in human neuroblastoma. Am J Pathol 1991; 139: 305-15
-
(1991)
Am J Pathol
, vol.139
, pp. 305-315
-
-
Bates, E.S.1
Shieh, C.Y.2
Tsokos, M.3
-
37
-
-
0031791723
-
Presence of classical multidrug resistance and P-glycoprotein expression in human neuroblastoma cells
-
37. Kurowski C, Berthold F. Presence of classical multidrug resistance and P-glycoprotein expression in human neuroblastoma cells. Ann Oncol 1998; 9: 1009-14
-
(1998)
Ann Oncol
, vol.9
, pp. 1009-1014
-
-
Kurowski, C.1
Berthold, F.2
-
38
-
-
0030752603
-
The CD95 (APO-1/Fas) System mediates drug-induced apoptosis in neuroblastoma cells
-
38. Fulda S, Sieverts H, Friesen C, et al. The CD95 (APO-1/Fas) System mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57: 3823-9
-
(1997)
Cancer Res
, vol.57
, pp. 3823-3829
-
-
Fulda, S.1
Sieverts, H.2
Friesen, C.3
-
39
-
-
0013674783
-
Chemotherapy of neuroblastoma
-
Pochedly C, editor. Boca Raton (FL): CRC Press Inc.
-
39. Castleberry RP. Chemotherapy of neuroblastoma. In: Pochedly C, editor. Neuroblastoma: tumor biology and therapy. Boca Raton (FL): CRC Press Inc., 1998: 306-16
-
(1998)
Neuroblastoma: Tumor Biology and Therapy
, pp. 306-316
-
-
Castleberry, R.P.1
-
40
-
-
0025758201
-
Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma
-
40. Cheung N-K, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991; 9: 1050-8
-
(1991)
J Clin Oncol
, vol.9
, pp. 1050-1058
-
-
Cheung, N.-K.1
Heller, G.2
-
41
-
-
0033950139
-
LMCE3 treatment strategy: Results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis
-
41. Frappaz D, Michon J, Coze C, et al. LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol 2000; 18: 468-76
-
(2000)
J Clin Oncol
, vol.18
, pp. 468-476
-
-
Frappaz, D.1
Michon, J.2
Coze, C.3
-
42
-
-
0024579424
-
Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy
-
42. Matthay K, Sather H, Seeger R, et al. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 1989; 7: 236-44
-
(1989)
J Clin Oncol
, vol.7
, pp. 236-244
-
-
Matthay, K.1
Sather, H.2
Seeger, R.3
-
43
-
-
0029739031
-
Successful management of low-stage neuroblastoma without adjuvant therapies: A comparison of two decades, 1972 through 1981 and 1982 through 1992 in a single institution
-
43. Evans A, Silber J, Shpilsky A, et al. Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992 in a single institution. J Clin Oncol 1997; 14: 2504-10
-
(1997)
J Clin Oncol
, vol.14
, pp. 2504-2510
-
-
Evans, A.1
Silber, J.2
Shpilsky, A.3
-
44
-
-
0002456398
-
Risk factors in neuroblastoma of infants
-
Harms Diagnose, Huber H, Queisser W, editors. Basel: S. Karger AG
-
44. Berthold F, Harms Diagnose, Lampert F, et al. Risk factors in neuroblastoma of infants, In: Huber H, Queisser W, editors. Contribution to oncology. Basel: S. Karger AG: 1990; 41: 101-17
-
(1990)
Contribution to Oncology
, vol.41
, pp. 101-117
-
-
Berthold, F.1
Lampert, F.2
-
45
-
-
0013654554
-
Neuroblastom
-
Schmoll H-J, Hoeffken K, Possinger K, editors. Berlin: Springer
-
45. Berthold F. Neuroblastom. In: Schmoll H-J, Hoeffken K, Possinger K, editors. Kompendium internistische onkologie. Berlin: Springer, 1999: 2389-402
-
(1999)
Kompendium Internistische Onkologie
, pp. 2389-2402
-
-
Berthold, F.1
-
46
-
-
0033004953
-
Long-term outcome of patients with intraspinal neuroblastoma
-
46. Hoover M, Bowman L, Crawford SE, et al. Long-term outcome of patients with intraspinal neuroblastoma. Med Pediatr Oncol 1999; 32: 353-9
-
(1999)
Med Pediatr Oncol
, vol.32
, pp. 353-359
-
-
Hoover, M.1
Bowman, L.2
Crawford, S.E.3
-
47
-
-
0025365117
-
The role of chemotherapy in the treatment of children with neuroblastoma stage IV: The GPO (German Pediatric Oncology Society) experience
-
47. Berthold F, Burdach S, Kremens B, et al. The role of chemotherapy in the treatment of children with neuroblastoma stage IV: the GPO (German Pediatric Oncology Society) experience. Klin Pädiatr 1990; 202: 262-9
-
(1990)
Klin Pädiatr
, vol.202
, pp. 262-269
-
-
Berthold, F.1
Burdach, S.2
Kremens, B.3
-
48
-
-
0032422239
-
Neuroblastoma and treatment-related myelodysplasia/leukemia: The memorial Sloan-Kettering experience and a literature review
-
48. Kushner BH, Cheung N-K, Kramer K, et al. Neuroblastoma and treatment-related myelodysplasia/leukemia: the memorial Sloan-Kettering experience and a literature review. J Clin Oncol 1998; 16: 3880-9
-
(1998)
J Clin Oncol
, vol.16
, pp. 3880-3889
-
-
Kushner, B.H.1
Cheung, N.-K.2
Kramer, K.3
-
49
-
-
0030854884
-
Positive selection and transplantation of peripheral CD34+ progenitor cells: Feasibility and purging efficacy in pediatric patients with neuroblastoma
-
49. Handgretinger R, Greil J, Schurmann U, et al. Positive selection and transplantation of peripheral CD34+ progenitor cells: feasibility and purging efficacy in pediatric patients with neuroblastoma. J Hematother 1997; 6: 235-42
-
(1997)
J Hematother
, vol.6
, pp. 235-242
-
-
Handgretinger, R.1
Greil, J.2
Schurmann, U.3
-
50
-
-
0344654819
-
Neuroblastoma cells can express the hematopoietic cell antigen CD34 as detected at surface protein an mRNA level
-
50. Hafer R, Voigt A, Gruhn B, et al. Neuroblastoma cells can express the hematopoietic cell antigen CD34 as detected at surface protein an mRNA level. J Neuroimmunol 1999; 96: 201-6
-
(1999)
J Neuroimmunol
, vol.96
, pp. 201-206
-
-
Hafer, R.1
Voigt, A.2
Gruhn, B.3
-
51
-
-
0023025419
-
Magnetic microspheres an monoclonal antibodies for the depletion of neuroblastoma cells from bone marrow: Experiences, improvements and observations
-
51. Kemshead JT, Heath L, Gibson FM, et al. Magnetic microspheres an monoclonal antibodies for the depletion of neuroblastoma cells from bone marrow: experiences, improvements and observations. Br J Cancer 1986; 54: 771-8
-
(1986)
Br J Cancer
, vol.54
, pp. 771-778
-
-
Kemshead, J.T.1
Heath, L.2
Gibson, F.M.3
-
52
-
-
0013695806
-
Increased incidence of secone leukemia after maintenance chemotherapy in neuroblastoma patients
-
52. Hero B, Niemeyer C, Dörffel W, et al. Increased incidence of secone leukemia after maintenance chemotherapy in neuroblastoma patients [abstract]. Med Pediatr Oncol 1996; 27: 303
-
(1996)
Med Pediatr Oncol
, vol.27
, pp. 303
-
-
Hero, B.1
Niemeyer, C.2
Dörffel, W.3
-
53
-
-
7144262406
-
An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma
-
53. Michon JM, Hartmann O, Bouffet E, et al. An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma. Eur J Cancer 1998; 34: 1063-9
-
(1998)
Eur J Cancer
, vol.34
, pp. 1063-1069
-
-
Michon, J.M.1
Hartmann, O.2
Bouffet, E.3
-
54
-
-
0030683515
-
Stem cell factor suppresses apoptosis in neuroblastoma cell lines
-
54. Timeus F, Crescenzio N, Valle P, et al. Stem cell factor suppresses apoptosis in neuroblastoma cell lines. Exp Hematol 1997; 25 : 1253-60
-
(1997)
Exp Hematol
, vol.25
, pp. 1253-1260
-
-
Timeus, F.1
Crescenzio, N.2
Valle, P.3
-
55
-
-
0003225107
-
Experimental therapeutics and new agents for neuroblastoma
-
Brodeur GM, Sawada T, Tsuchida Y, et al., editors. Amsterdam: Elsevier Press
-
55. Vassal G, Pinkerton R. Experimental therapeutics and new agents for neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, et al., editors. Neuroblastoma. Amsterdam: Elsevier Press, 2000: 383-92
-
(2000)
Neuroblastoma
, pp. 383-392
-
-
Vassal, G.1
Pinkerton, R.2
-
56
-
-
0031934032
-
Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumor: A pediatric oncology group study
-
56. Saylors R, Stewart C, Zamboni W, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumor: a pediatric oncology group study. J Clin Oncol 1998; 16: 945-52
-
(1998)
J Clin Oncol
, vol.16
, pp. 945-952
-
-
Saylors, R.1
Stewart, C.2
Zamboni, W.3
|